A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses

<em><strong>Objective(s):</strong></em> Infection with tuberculosis (TB) is regarded as a major health issue. Due to the emergence of antibiotic resistance during TB treatment, prevention via vaccination is one of the most effective ways of controlling the infection. DNA vacc...

Full description

Bibliographic Details
Main Authors: Bagher Moradi, Mojtaba Sankian, Yousef Amini, Aida Gholoobi, Zahra Meshkat
Format: Article
Language:English
Published: Mashhad University of Medical Sciences 2020-07-01
Series:Iranian Journal of Basic Medical Sciences
Subjects:
bcg
dna
Online Access:http://ijbms.mums.ac.ir/article_15571_2f7a631adf8413ee1bc9ce23ef142c9f.pdf
id doaj-72323ababd344f788885e9a51ea15510
record_format Article
spelling doaj-72323ababd344f788885e9a51ea155102020-11-25T03:06:13ZengMashhad University of Medical SciencesIranian Journal of Basic Medical Sciences 2008-38662008-38742020-07-0123790991410.22038/ijbms.2020.38521.917115571A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responsesBagher Moradi0Mojtaba Sankian1Yousef Amini2Aida Gholoobi3Zahra Meshkat4Esfarayen Faculty of Medical Sciences, Esfarayen, IranImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, IranInfectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, IranMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran<em><strong>Objective(s):</strong></em> Infection with tuberculosis (TB) is regarded as a major health issue. Due to the emergence of antibiotic resistance during TB treatment, prevention via vaccination is one of the most effective ways of controlling the infection. DNA vaccines are developed at a greater pace due to their ability in generating a long-lasting immune response, higher safety compared to the live vaccines, and relatively lower cost of production. In the present study, we evaluated a new DNA vaccine encoding the fusion HspX-PPE44-EsxV antigens, separately, and in combination with Bacillus Calmette–Guérin (BCG) administration, in a prime-boost method in mice.<br /><em><strong>Materials and Methods:</strong></em> A novel DNA vaccine encoding HspX-PPE44-EsxV fusion antigen of Mycobacterium tuberculosis was constructed, and RT-PCR and Western blot analysis were performed to verify the expression of the antigen. Female BALB/c mice were divided into five groups (PBS, BCG, pcDNA3.1 (+) vector, pDNA/HspX-PPE44-EsxV vaccine, and the BCG-prime boost groups).  In order to evaluate the immunogenicity of the recombinant vector, BALB/c mice were injected with 100 μg of pDNA at 2-week intervals. Then, cytokine assay was conducted using eBioscience ELISA kits (Ebioscience, AUT) according to manufacturers’ instructions to evaluate the concentrations of IL-4, IL-12, TGF-β, and IFN-γ.<br /><em><strong>Results:</strong></em> The concentrations of INF-γ, IL-12, and TGF-beta were significantly increased compared to the control groups (P<0.001). INF-γ and IL-12 production were increased significantly in pDNA/HspX-PPE44-EsxV+BCG group compared to pDNA/HspX-PPE44-EsxV group (P<0.001).<br /><em><strong>Conclusion:</strong></em> This study showed that the present DNA vaccine could induce a high level of specific cytokines in mice. It was also shown that using this DNA vaccine in a BCG prime-boost protocol can produce significant amounts of IFN-γ, IL-12, and TGF-β.http://ijbms.mums.ac.ir/article_15571_2f7a631adf8413ee1bc9ce23ef142c9f.pdfbcgdnamycobacterium tuberculosis pcrvaccine
collection DOAJ
language English
format Article
sources DOAJ
author Bagher Moradi
Mojtaba Sankian
Yousef Amini
Aida Gholoobi
Zahra Meshkat
spellingShingle Bagher Moradi
Mojtaba Sankian
Yousef Amini
Aida Gholoobi
Zahra Meshkat
A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
Iranian Journal of Basic Medical Sciences
bcg
dna
mycobacterium tuberculosis pcr
vaccine
author_facet Bagher Moradi
Mojtaba Sankian
Yousef Amini
Aida Gholoobi
Zahra Meshkat
author_sort Bagher Moradi
title A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
title_short A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
title_full A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
title_fullStr A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
title_full_unstemmed A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
title_sort new dna vaccine expressing hspx-ppe44-esxv fusion antigens of mycobacterium tuberculosis induced strong immune responses
publisher Mashhad University of Medical Sciences
series Iranian Journal of Basic Medical Sciences
issn 2008-3866
2008-3874
publishDate 2020-07-01
description <em><strong>Objective(s):</strong></em> Infection with tuberculosis (TB) is regarded as a major health issue. Due to the emergence of antibiotic resistance during TB treatment, prevention via vaccination is one of the most effective ways of controlling the infection. DNA vaccines are developed at a greater pace due to their ability in generating a long-lasting immune response, higher safety compared to the live vaccines, and relatively lower cost of production. In the present study, we evaluated a new DNA vaccine encoding the fusion HspX-PPE44-EsxV antigens, separately, and in combination with Bacillus Calmette–Guérin (BCG) administration, in a prime-boost method in mice.<br /><em><strong>Materials and Methods:</strong></em> A novel DNA vaccine encoding HspX-PPE44-EsxV fusion antigen of Mycobacterium tuberculosis was constructed, and RT-PCR and Western blot analysis were performed to verify the expression of the antigen. Female BALB/c mice were divided into five groups (PBS, BCG, pcDNA3.1 (+) vector, pDNA/HspX-PPE44-EsxV vaccine, and the BCG-prime boost groups).  In order to evaluate the immunogenicity of the recombinant vector, BALB/c mice were injected with 100 μg of pDNA at 2-week intervals. Then, cytokine assay was conducted using eBioscience ELISA kits (Ebioscience, AUT) according to manufacturers’ instructions to evaluate the concentrations of IL-4, IL-12, TGF-β, and IFN-γ.<br /><em><strong>Results:</strong></em> The concentrations of INF-γ, IL-12, and TGF-beta were significantly increased compared to the control groups (P<0.001). INF-γ and IL-12 production were increased significantly in pDNA/HspX-PPE44-EsxV+BCG group compared to pDNA/HspX-PPE44-EsxV group (P<0.001).<br /><em><strong>Conclusion:</strong></em> This study showed that the present DNA vaccine could induce a high level of specific cytokines in mice. It was also shown that using this DNA vaccine in a BCG prime-boost protocol can produce significant amounts of IFN-γ, IL-12, and TGF-β.
topic bcg
dna
mycobacterium tuberculosis pcr
vaccine
url http://ijbms.mums.ac.ir/article_15571_2f7a631adf8413ee1bc9ce23ef142c9f.pdf
work_keys_str_mv AT baghermoradi anewdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT mojtabasankian anewdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT yousefamini anewdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT aidagholoobi anewdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT zahrameshkat anewdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT baghermoradi newdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT mojtabasankian newdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT yousefamini newdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT aidagholoobi newdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
AT zahrameshkat newdnavaccineexpressinghspxppe44esxvfusionantigensofmycobacteriumtuberculosisinducedstrongimmuneresponses
_version_ 1724674561069285376